Emergence of Acquired HIV-1 Drug Resistance Almost Stopped in Switzerland: A 15-Year Prospective Cohort Analysis
Open Access
- 8 March 2016
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 62 (10) , 1310-1317
Abstract
Background. Drug resistance is a major barrier to successful antiretroviral treatment (ART). Therefore, it is important to monitor time trends at a population level. Methods. We included 11 084 ART-experienced patients from the Swiss HIV Cohort Study (SHCS) between 1999 and 2013. The SHCS is highly representative and includes 72% of patients receiving ART in Switzerland. Drug resistance was defined as the presence of ≥1 major mutation in a genotypic resistance test. To estimate the prevalence of drug resistance, data for patients with no resistance test was imputed based on the patient's risk of harboring drug-resistant viruses. Results. The emergence of new drug resistance mutations declined dramatically from 401 to 23 patients between 1999 and 2013. The upper estimated prevalence limit of drug resistance among ART-experienced patients decreased from 57.0% in 1999 to 37.1% in 2013. The prevalence of 3-class resistance decreased from 9.0% to 4.4% and was always Conclusions. Human immunodeficiency virus type 1 drug resistance among ART-experienced patients in Switzerland is a well-controlled relic from the era before combination ART. Emergence of drug resistance can be virtually stopped with new potent therapies and close monitoring.Keywords
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (33CS30_148522, PZ00P3-142411, 320030_159868)
This publication has 31 references indexed in Scilit:
- Trends in Antiretroviral Therapy and Prevalence of HIV Drug Resistance Mutations in Sweden 1997–2011PLOS ONE, 2013
- HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational studyThe Lancet Infectious Diseases, 2011
- Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007–2009Clinical Microbiology and Infection, 2011
- Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort StudyHIV Medicine, 2010
- Cohort Profile: The Swiss HIV Cohort StudyInternational Journal of Epidemiology, 2009
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Raltegravir with Optimized Background Therapy for Resistant HIV-1 InfectionNew England Journal of Medicine, 2008
- Antiretroviral Drug Resistance Testing in Adult HIV‐1 Infection: 2008 Recommendations of an International AIDS Society–USA PanelClinical Infectious Diseases, 2008
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989